Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

Earnings: Discover insights into revenue shifts, cost reductions, 2027 product goals, RSV market strategies, and its broader ...

Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends in the pharmaceutical sector.